2023-508661-33-00RecruitingPhase 1
A clinical study to assess if a new investigational medicinal product called JJP-1212 is safe, tolerable and able to induce a specific immune response in humans
Source: EU CTIS (euclinicaltrials.eu) · Last updated 30 Oct 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 76 (estimated)
- First submitted
- 14 Feb 2024
- Start date
- 29 May 2024
- Lead sponsor
- Jjp Biologics Sp. z o.o.
- Diseases
- Rheumatoid arthritis
- EU CT number
- 2023-508661-33-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 76
- 2 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Alexandrovska University Hospital | Sofia | Bulgaria | Not yet recruiting |
| MTZ Clinical Research powered by Pratia | Warsaw | Poland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.